O-021Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). (2nd July 2019) - Meyer, T; Finn, R; Kudo, M; Kang, Y; Yen, C; Galle, P; Llovet, J; Assenat, E; Brandi, G; Motomura, K; Okusaka, T; Hubner, R; et al.